{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:39:59Z","timestamp":1792798799750,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.kint.2026.09.026","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:23:01Z","timestamp":1792509781000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial"],"prefix":"10.1016","author":[{"given":"Katherine R.","family":"Tuttle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit R.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Arici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ecenur Guder","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Bellary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Idorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdravko","family":"Kamenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F.E.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip Andreas","family":"Schytz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Sreenivasamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Pratley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.09.026_bib1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.09.026_bib2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.kint.2026.09.026_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/phar.70014","article-title":"Updates in chronic kidney disease management: a systematic review","volume":"45","author":"Ammar","year":"2025","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.kint.2026.09.026_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110592","article-title":"Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials","volume":"198","author":"Yang","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.kint.2026.09.026_bib5","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.kint.2026.09.026_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.kint.2026.09.026_bib7","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1111\/dom.16398","article-title":"Comparative efficacy and tolerability of currently approved incretin mimetics: a systematic analysis of placebo-controlled clinical trials","volume":"27","author":"Kang","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.kint.2026.09.026_bib8","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.09.026_bib9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2026.09.026_bib10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/14796678.2025.2511412","article-title":"Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome","volume":"21","author":"MacIsaac","year":"2025","journal-title":"Future Cardiol"},{"key":"10.1016\/j.kint.2026.09.026_bib11","first-page":"560","article-title":"To study the risk factors, treatment and outcomes of acute kidney injury in intensive care unit patients","volume":"15","author":"Barik","year":"2025","journal-title":"Eur J Cardiovasc Med"},{"key":"10.1016\/j.kint.2026.09.026_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2024.2397555","article-title":"The association between acute kidney injury and dysglycaemia in critically ill patients with and without diabetes mellitus: a retrospective single-center study","volume":"46","author":"Zhang","year":"2024","journal-title":"Ren Fail"},{"key":"10.1016\/j.kint.2026.09.026_bib13","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2215\/CJN.00800209","article-title":"Frequency of hypoglycemia and its significance in chronic kidney disease","volume":"4","author":"Moen","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.09.026_bib14","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/ckj\/sfac096","article-title":"Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice","volume":"15","author":"Aviles","year":"2022","journal-title":"Clin Kidney J"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826008471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826008471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:04:13Z","timestamp":1792796653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826008471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":14,"alternative-id":["S0085253826008471"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.09.026","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}